Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053547 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
A Phase 4 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT00053547 is a Phase 4 study that has completed, run by Abbott. The registered enrollment target is 28 participants.
The verdict
NCT00053547, a Phase 4 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
Interventions
- DRUG paricalcitol injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053547
The ClinicalTrials.gov registry entry for NCT00053547 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paricalcitol injection is the first listed.
NCT00053547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053547 about?
NCT00053547 is a clinical study titled "Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis". The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
What is the current status of trial NCT00053547?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2002-01.
What interventions are being tested in trial NCT00053547?
The interventions under investigation include: paricalcitol injection (DRUG).
Who is sponsoring clinical trial NCT00053547?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.